AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12638834 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐gauge Gertie Marx needle
Number of subjects: 60
Study 12638834 — intervention group
Group type: COMPARATOR
Intervention: 25‐gauge Quincke needle
Number of subjects: 60
Study 9588720 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0
Study 9588720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic mapping with sentinel lymph node biopsy
Number of subjects: 0
Study 9588720 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care without ELND)
Number of subjects: 0
Study 8813312 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 910
Study 8813312 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 910
Study 8813312 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher parity
Number of subjects: 910
Study 8813312 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 910
Study 8813312 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 910
Study 2299491 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 41
Study 2299491 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 41
Study 7235806 — intervention group
Group type: EXPERIMENTAL
Intervention: Percussion measurement of diaphragmatic excursion
Number of subjects: 29
Study 29357754 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated euthanasia for cancer or depression
Number of subjects: 324
Study 29357754 — intervention group
Group type: COMPARATOR
Intervention: Family-initiated euthanasia for cancer or depression
Number of subjects: 324
Study 29357754 — intervention group
Group type: COMPARATOR
Intervention: Euthanasia attitudes for schizophrenia
Number of subjects: 324
Study 29357754 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward euthanasia based on illness type
Number of subjects: 324
Study 31584919 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation
Number of subjects: 40
Study 31584919 — intervention group
Group type: COMPARATOR
Intervention: Conventional facemask oxygenation
Number of subjects: 40
Study 28483629 — intervention group
Group type: EXPERIMENTAL
Intervention: DACC-coated postoperative dressings
Number of subjects: 200
Study 28483629 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 200
Study 25330734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 196
Study 25330734 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 196
Study 24903195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic Balloon Pump (IABP) therapy
Number of subjects: 190
Study 24903195 — intervention group
Group type: COMPARATOR
Intervention: No IABP therapy (Control)
Number of subjects: 190
Study 21868369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 20
Study 21868369 — intervention group
Group type: COMPARATOR
Intervention: Standard management alone
Number of subjects: 20
Study 20371445 — intervention group
Group type: EXPERIMENTAL
Intervention: ESHAP (etoposide, methylprednisolone, cytosine arabinoside, and platinum)
Number of subjects: 100
Study 20371445 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ESHAP (rituximab plus ESHAP)
Number of subjects: 100
Study 17442202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diver CE device
Number of subjects: 122
Study 17442202 — intervention group
Group type: COMPARATOR
Intervention: Guardwire Plus device
Number of subjects: 122
Study 15803031 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (maintenance therapy)
Number of subjects: 10
Study 15803031 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (first dose)
Number of subjects: 10
Study 15803031 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (combined groups)
Number of subjects: 10
Study 11943119 — intervention group
Group type: EXPERIMENTAL
Intervention: error+correct training
Number of subjects: 30
Study 11943119 — intervention group
Group type: COMPARATOR
Intervention: correct only training
Number of subjects: 30
Study 11943119 — intervention group
Group type: COMPARATOR
Intervention: error only training
Number of subjects: 30
Study 11943119 — intervention group
Group type: EXPERIMENTAL
Intervention: error training for faculty raters
Number of subjects: 30
Study 11943119 — intervention group
Group type: COMPARATOR
Intervention: no training for faculty raters
Number of subjects: 30
Study 10567780 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg once daily)
Number of subjects: 35
Study 10567780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 35
Study 10567780 — intervention group
Group type: COMPARATOR
Intervention: Comparison of gemifloxacin vs placebo
Number of subjects: 35
Study 7848022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine resin, 8 g/d
Number of subjects: 26
Study 7848022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine resin, 8 g/d plus lovastatin, 5 mg/d
Number of subjects: 26
Study 7848022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 20 mg/d
Number of subjects: 26
Study 2179146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 31
Study 2179146 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise training
Number of subjects: 31
Study 2179146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 343795 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 30
Study 343795 — intervention group
Group type: COMPARATOR
Intervention: Reserpine
Number of subjects: 30
Study 343795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31764336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough trick during drain removal
Number of subjects: 56
Study 31764336 — intervention group
Group type: COMPARATOR
Intervention: Usual process without cough trick
Number of subjects: 56
Study 31764336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough trick
Number of subjects: 56
Study 27914839 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL repositioning by scleral suturing (n = 54)
Number of subjects: 104
Study 27914839 — intervention group
Group type: COMPARATOR
Intervention: IOL exchange with retropupillary fixation of an iris-claw IOL (n = 50)
Number of subjects: 104
Study 26048388 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentricity index measured from pre‐procedural CT/MR imaging
Number of subjects: 38
Study 24156137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% arginine and 1450 ppm fluoride as sodium monofluorophosphate in a calcium base (experimental)
Number of subjects: 412
Study 24156137 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride as sodium fluoride in a silica base (positive control)
Number of subjects: 412
Study 24156137 — intervention group
Group type: COMPARATOR
Intervention: No fluoride in a calcium base (negative control)
Number of subjects: 412
Study 21560649 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0
Study 21560649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study 21560649 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 21560649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative anti-inflammatory drug based on ginger extract
Number of subjects: 0
Study 19399932 — intervention group
Group type: EXPERIMENTAL
Intervention: Case A (shorter and almost straight duodenal section)
Number of subjects: 0
Study 19399932 — intervention group
Group type: EXPERIMENTAL
Intervention: Case B (longer and curved duodenal section)
Number of subjects: 0
Study 16721468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical method (Carisolv)
Number of subjects: 30
Study 16721468 — intervention group
Group type: COMPARATOR
Intervention: Hand excavation
Number of subjects: 30
Study 15003074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (100-500 mg/day)
Number of subjects: 124
Study 15003074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 11136631 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented partial hospitalization program
Number of subjects: 44
Study 11136631 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric care
Number of subjects: 44
Study 9779760 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with bacteriologic eradication
Number of subjects: 123
Study 9779760 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment without bacteriologic eradication
Number of subjects: 123
Study 9676769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (250 mg/day)
Number of subjects: 0
Study 9676769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50-100 mg every 4-6 h as needed for pain)
Number of subjects: 0
Study 9676769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 9676769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2561281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 50
Study 2561281 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (N)
Number of subjects: 50
Study 2561281 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (S)
Number of subjects: 50
Study 2561281 — intervention group
Group type: COMPARATOR
Intervention: Initial control (C)
Number of subjects: 50
Study 2561281 — intervention group
Group type: COMPARATOR
Intervention: Final control (C')
Number of subjects: 50
Study 54740 — intervention group
Group type: EXPERIMENTAL
Intervention: Laundering and vacuum-cleaning bedclothes and pillows, applying a plastic cover to the mattress for six weeks
Number of subjects: 32
Study 54740 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 32
Study 30952531 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (ET) including mechanical thrombectomy (MT) alone (N = 269), MT ± thrombolysis (N = 297), and thrombolysis alone (N = 682)
Number of subjects: 49952
Study 30952531 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 49952
Study 27872067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 333
Study 26121495 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS) 50 mg
Number of subjects: 67
Study 26121495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23926685 — intervention group
Group type: EXPERIMENTAL
Intervention: NGN decoction
Number of subjects: 60
Study 23926685 — intervention group
Group type: COMPARATOR
Intervention: Control (testosterone undecanoate capsules)
Number of subjects: 60
Study 20619411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing guideline 'depression in dementia' introduced on experimental wards
Number of subjects: 193
Study 20619411 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided on control wards
Number of subjects: 193
Study 19299427 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan alone
Number of subjects: 392
Study 19299427 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril alone
Number of subjects: 392
Study 19299427 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan plus enalapril
Number of subjects: 392
Study 16952675 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg tamsulosin daily
Number of subjects: 48
Study 16952675 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alfuzosin daily
Number of subjects: 48
Study 16952675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15459134 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 11735088 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate alone (Cr; n = 10)
Number of subjects: 30
Study 11735088 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine plus resistance training (Cr-RT; n = 10)
Number of subjects: 30
Study 11735088 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus resistance training (P-RT; n = 10)
Number of subjects: 30
Study 9131726 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin administered intravenously (125 mg) switched to oral administration (250 mg)
Number of subjects: 0
Study 9131726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 0
Study 7641549 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment (totally pre-peritoneal approach)
Number of subjects: 124
Study 7641549 — intervention group
Group type: COMPARATOR
Intervention: Shouldice operation
Number of subjects: 124
Study 7641549 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 124
Study 2567717 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal suppositories (PVS)
Number of subjects: 100
Study 2567717 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BCT)
Number of subjects: 100
Study 31144430 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose 50 mg for 1 week
Number of subjects: 11
Study 31144430 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg for 1 week
Number of subjects: 11
Study 31144430 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 120 mg for 1 week
Number of subjects: 11
Study 31144430 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg for 3 weeks
Number of subjects: 11
Study 31144430 — intervention group
Group type: EXPERIMENTAL
Intervention: pasireotide 300 μg as a single dose
Number of subjects: 11
Study 31144430 — intervention group
Group type: COMPARATOR
Intervention: baseline period without treatment
Number of subjects: 11
Study 28608641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive immunosuppressive regimen (including ATG, steroid therapy, high CNI doses)
Number of subjects: 105
Study 28608641 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard immunosuppressive regimen)
Number of subjects: 105
Study 25503377 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to anti-POS advertising
Number of subjects: 0
Study 23416811 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrate transfusion
Number of subjects: 42
Study 21526229 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily micronutrient-rich nutritional supplement
Number of subjects: 2799
Study 21526229 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 1-hour physical activity classes per week
Number of subjects: 2799
Study 21526229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (nutritional supplement and physical activity)
Number of subjects: 2799
Study 21526229 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 2799
Study 18843004 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein intake containing 99 mg isoflavones daily
Number of subjects: 202
Study 18843004 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (placebo)
Number of subjects: 202
Study 17057564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4 Hz, 200 micros)
Number of subjects: 90
Study 17057564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (110 Hz, 200 micros)
Number of subjects: 90
Study 17057564 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 90
Study 12633642 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping (CARTO)
Number of subjects: 20
Study 12633642 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic mapping
Number of subjects: 20
Study 11140145 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategic group program (18 weeks, 2 meetings per week, 1.5 hours each) including physical exercises, psychomusical techniques, cognitive games, and tasks related to IADL
Number of subjects: 11
Study 11140145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 11
Study 8759268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphapyridine 500 mg twice daily
Number of subjects: 20
Study 1467453 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 25 micrograms
Number of subjects: 14
Study 1467453 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 50 micrograms
Number of subjects: 14
Study 1467453 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 75 micrograms
Number of subjects: 14
Study 1467453 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol 100 micrograms
Number of subjects: 14
Study 10274896 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact smoking cessation intervention (brief consultation, self-help manual, incentive)
Number of subjects: 213
Study 10274896 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact smoking cessation intervention
Number of subjects: 213
Study 31068395 — intervention group
Group type: EXPERIMENTAL
Intervention: Boot Camp Translation (BCT) approach for refining colon cancer screening messages
Number of subjects: 25
Study 28838010 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2) at 10 L/min via facemask
Number of subjects: 70
Study 28838010 — intervention group
Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 70
Study 27412188 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 638
Study 27412188 — intervention group
Group type: COMPARATOR
Intervention: Control (discontinue all hypertensive medications)
Number of subjects: 638
Study 25262306 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention based on the Chronic Care Model, Stanford Expert Patient Programme, and Kaiser Permanente model.
Number of subjects: 1606
Study 25262306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 1606
Study 22464031 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 80
Study 22464031 — intervention group
Group type: COMPARATOR
Intervention: Pragmatic training (Control)
Number of subjects: 80
Study 20219292 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OMPH)
Number of subjects: 253
Study 20219292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 20219292 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in desire to smoke
Number of subjects: 253
Study 18923311 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual physical therapy and exercise (MTE)
Number of subjects: 94
Study 18923311 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (MIN)
Number of subjects: 94
Study 16092046 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of exercise (30 minutes)
Number of subjects: 9
Study 16092046 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple bouts of exercise (3 x 10 minutes)
Number of subjects: 9
Study 16092046 — intervention group
Group type: COMPARATOR
Intervention: Control day (no exercise)
Number of subjects: 9
Study 16092046 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 women, 49 +/- 4 years old)
Number of subjects: 9
Study 12519101 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine therapy
Number of subjects: 17
Study 10355619 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction (VN)
Number of subjects: 24
Study 10355619 — intervention group
Group type: COMPARATOR
Intervention: Written instructions (NV)
Number of subjects: 24
Study 7769807 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.25 mg/h
Number of subjects: 45
Study 7769807 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.5 mg/h
Number of subjects: 45
Study 7769807 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 45
Study 2022712 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (22 mumol/kg.h)
Number of subjects: 0
Study 2022712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2022712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10-amino acid mixture
Number of subjects: 0
Study 2022712 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK octapeptide (CCK-8) at 8.6 pmol/kg.h
Number of subjects: 0
Study 2022712 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 with loxiglumide
Number of subjects: 0
Study 7066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 0
Study 7066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Number of subjects: 0
Study 7066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 0
Study 7066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg
Number of subjects: 0
Study 7066166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg
Number of subjects: 0
Study 7066166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31597046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU)
Number of subjects: 36
Study 31597046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31914294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing combined with three-dimensional reconstruction operation
Number of subjects: 40
Study 31914294 — intervention group
Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 40
Study 28919328 — intervention group
Group type: COMPARATOR
Intervention: C-peptide levels (0–33%)
Number of subjects: 1263
Study 28919328 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels (34–66%)
Number of subjects: 1263
Study 28919328 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels (67–90%)
Number of subjects: 1263
Study 28919328 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels (> 90%)
Number of subjects: 1263
Study 26281178 — intervention group
Group type: EXPERIMENTAL
Intervention: Livodexa (Sun Pharmaceutical Industries Ltd, India)
Number of subjects: 68